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Letters to the Editorapproach allows the use of the whole
lumen of the artery for perfusion,
thus avoiding high pressure gradients
across the cannula. The risk of infec-
tion of the vascular prosthesis in
cases of longer extracorporeal mem-
brane oxygenation perfusion has to
be weighted against potential diam-
eter limitations of the perfusion
cannula and complications of the
distal perfusion cannula technique
(kinking, dislocation, thrombosis).
I thank Banfi and colleagues for
their interest in our work and their
mindful comments.
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j.jtcvs.2014.02.067REPLY TO ‘‘IS THE CAUSE OF
DEATH IN HYPERTROPHIC
CARDIOMYOPATHY LOW
PRESSURE GRADIENT IN LEFT
VENTRICULAR OUTFLOW?’’
Reply to the Editor:
Kestelli and associates1 may have
misunderstood the analysis in my
group’s article, ‘‘Expanding the
Indications for Septal Myectomy in
Patients With Hypertrophic Cardio-
myopathy: Results of Operation inThe JournalPatients With Latent Obstruction.’’2
As shown in Table 2 in our original
article,2 preoperative medication use
was generally similar between the pa-
tientswith latent obstruction (gradients
of 30 mm Hg or less) and those with
high resting gradients (greater than
30 mm Hg). We did not analyze sur-
vival according to preoperative drug
use, and if, in fact, medications
had any substantial impact on late sur-
vival, such an effect would likely be
related to postoperative medication
use rather than to preoperative medica-
tion use.
We did not postulate that wall thick-
ness had any impact on survival one
way or the other. In our previous
studies, however, left ventricular
mass and wall thickness were not
found to be predictors of late survival
after myectomy for hypertrophic
obstructive cardiomyopathy, a finding
that is in contrast to the results of nat-
ural history studies of patients who
were not treated surgically.3
The apparent minor difference in
survival of patients with latent
obstruction in our original Figures 2
and 4 is actually due to a slight differ-
ence in the number of patients for
whom matching was possible in the
age-matched and sex-matched
population.
The conclusion drawn by Kestelli
and associates1 from the article by
Ommen and colleagues4 is incorrect.
In that series, which also came from
our clinic, the late survival of patients
with obstructive hypertrophic cardio-
myopathy who underwent myectomy
was similar to the survival of patients
who had hypertrophic cardiomyopa-
thy without obstruction. Left ventricu-
lar outflow tract obstruction left
untreated in patients with hypertro-
phic cardiomyopathy is associated
with reduced late survival,5 and this
situation seems to be improved after
myectomy.
Hartzell Schaff, MD
Division of Thoracic and
Cardiovascular Surgeryof Thoracic and Cardiovascular SurgerMayo Clinic
Rochester, Minn
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LOBECTOMY BE REPLACED
BY SUBLOBAR RESECTION
IN PATIENTS WITH STAGE I
NON–SMALL CELL LUNG
CANCER?
To the Editor:
We read with interest the article by
Altorki and colleagues1 comparing
survival between patients treated
by sublobar (SLR) and lobar (LR)
resection for clinical stage IA
non–small cell lung cancer. SLR
is commonly considered only for
patients who cannot undergo
lobectomy. This practice is based on
a randomized trial published by the
Lung Cancer Study Group in 1995,2
which showed LR to be associated
with lower rates of local recurrence
and cancer-related death. In contrast,
Altorki and colleagues1 found
equivalent survival between SLR
and LR in clinical stage IA. We
congratulate them for this studyy c Volume 147, Number 6 1997
Letters to the Editorand believe that in the future their
conclusions could radically change
and enlarge the role of SLR in the
treatment of patients with non–small
cell lung cancer.
Our most important concern,
however, lies in the cases of
unexpected N1 or N2 disease, ranging
from 4% to 7% in the experience of
Altorki and colleagues1 and reported
at similar levels in the most recent
literature. In this group of patients
with disease upstaged to stage II or
III, SLR is not indicated and LR is
certainly the optimal treatment.3
In addition, we would like to focus
the attention on some features that
could limit the meaning of the study.
First, their results are based on a pop-
ulation enrolled in the International
Early Lung Cancer Action Program
(I-ELCAP) group according to spe-
cific criteria.4 This very uniform pop-
ulation may not represent the general
population of a daily clinical practice.
Second, this was not a randomized
study, and the criteria used by the
different surgeons to decide whether
to perform LR or SLR and the surgical
approach adopted are not reported.
Third, there were some patients in
both groups who did not undergo a
complete nodal sampling. This could
lead to incorrect staging and influence
survival results. Finally, in our experi-
ence and according to several studies,
wedge resection is associated with a
higher rate of recurrence than is seg-
mentectomy. This gap could be deter-
mined by several factors, such as
smaller parenchymal margin and
lower yield of lymph nodes.5 Also,
Altorki and colleagues1 in their study
reported that segmentectomy was
associated with a lower recurrence
rate than was wedge resection.
Despite this, LR and wedge SRL
have the same survival. We underline
that wedge resection and segmentec-
tomy are not oncologically equivalent
and suggest that they be considered
separately.
In conclusion, Altorki and col-
leagues1 report interesting data, but1998 The Journal of Thoracic andthe topic might be better investigated
with a randomized study to draw
definitive conclusions.
Alessandro Baisi, MD
Matilde De Simone, MD, PhD
Ugo Cioffi, MD, PhD
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j.jtcvs.2014.02.070RELATIVE AMPLITUDE INDEX:
A NEW TOOL FOR
HEMODYNAMIC EVALUATION
OF PERIPROSTHETIC
REGURGITATION AFTER
TRANSCATHETER VALVE
IMPLANTATION
To the Editor:
Heinz and colleagues1 present an
interesting concept to help clinicians
assess the severity of paravalvular
leakage (PVL) after transaortic valve
insertion; however, their report raises
a number of issues.
The association of PVL severity as
assessed by echocardiography and
poor outcomes after transcatheter
aortic valve implantation is well
known.2 It will be difficult to adoptCardiovascular Surgery c June 2014the relative amplitude index (RAI)
as a new marker compared with
an echocardiographic assessment,
because the authors have not pre-
sented data on the outcomes for pa-
tients with a mild PVL on the
echocardiogram and a high RAI
versus severe PVL and a low RAI.
With regard to the statistical
analysis, no correlation coefficient
was presented for PVL severity
and RAI. The PVL severity and
RAI are almost certainly related;
however, no interaction analysis
was performed for mortality or
long-term survival. The univariate
analysis of death did not include
age, Agatston score, or annular ec-
centricity as covariates, probably
the most important factors in deter-
mining PVL severity.3 In addition,
perioperative respiratory failure
had the greatest odds ratio for
death, but preoperative chronic
obstructive pulmonary disease was
not significant, implying that tech-
nical issues at implantation could
be an issue. No correlation between
the RAI and perioperative compli-
cations were presented. An RAI
cutoff value of 14 was deduced
from the receiver operating curve
analysis; however, no sensitivity or
specificity data were presented.
Also, only 7 of the 110 patients in
the cohort had an RAI of 14, sug-
gesting general applicability might
be an issue. With regard to mortal-
ity, we question their finding of a
significant difference (P ¼ .013,
Table 2), because we calculated
the mortality difference as nonsig-
nificant (P ¼ .1).
The formula presented for the deri-
vation of RAI was not referenced or
derived in their report, and, despite
the simplicity, we believe, from a
mathematical and engineering view-
point, is incorrect, according to previ-
ous reports.4,5
BPd-pre ¼ Fd$SVRpre (1)
